REPORT DOCUMENTATION PAGE					0	Form Approved OMB No. 0704-0188		
The public reporting burden for this coll gathering and maintaining the data needer information, including suggestions for rec 1215 Jefferson Davis Highway, Suite 12 penalty for failing to comply with a collect PLEASE DO NOT RETURN YOU	ection of information d, and completing and lucing the burden, to 04, Arlington, VA 2. tion of information if i R FORM TO TH	is estimated to average 1 hou dreviewing the collection of info Department of Defense, Wash 2202-4302. Respondents shor t does not display a currently vi IE ABOVE ADDRESS.	ur per response, incl ormation. Send com ington Headquarters uld be aware that no alid OMB control nur	luding the tir iments regard s Services, Di otwithstandir mber.	ne for reviewing ins ling this burden estir irectorate for Inform ng any other provisio	structions, searching existing data sources, mate or any other aspect of this collection of ation Operations and Reports (0704-0188), on of law, no person shall be subject to any		
1. REPORT DATE (DD-MM-YY	REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE					3. DATES COVERED (From - To)		
12/07/2012	12/07/2012 Quarterly Technical Report				10/01/2012 - 12/31/2012			
4. TITLE AND SUBTITLE			5a. CONTRACT NUMBER					
Human Neural Cell-Based Biosensor					N00014-11-C-0011, Mod. P00002			
			5b. GRANT NUMBER					
					5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S)					5d. PROJECT NUMBER			
Stice. Steven L								
Chilton, Jamie								
					5e. TASK NUMBER			
				5f. WORK UNIT NUMBER				
7. PERFORMING ORGANIZATI	ON NAME(S) AN	ID ADDRESS(ES)			8. PERFORMIN	UMBER		
ArunA Biomedical, Inc.						$OTR_{-111020107}$		
425 River Road						Q1R-11102010.7		
Athens, GA 30002								
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)					10. SPONSOR/MONITOR'S ACRONYM(S)			
Director, Naval Research La	h				DoD/ONR			
Attn: Code 5596	0							
4555 Overlook Avenue, SW					11. SPONSOR/MONITOR'S REPORT			
Washington, D.C. 20375-53	20		NUMBER(S)					
			ONR 5252.235-9714					
12. DISTRIBUTION/AVAILABILITY STATEMENT								
Approved for public release; distribution is unlimited.								
13. SUPPLEMENTARY NOTES								
14. ABSTRACT								
Our goal is to provide a more biologically relevant model of human physiology for the purpose of developing in vitro, cell based biosensors for environmental toxins. Specifically we plan to develop human neural based biosensors by using ArunA's neural cell lines derived from both human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).								
This report describes the prop progenitor cells into dopamin astrocytes; (3) label-free, adh	gress made in t nergic neurons; nesive signature	hese major areas: (1) o (2) directed differenti e-based microfluidic c	directed differ ation of hESC ell separation;	entiation 2- and hiF and (4) r	of hESC- and PSC-derived not neural crest dif	hiPSC-derived neural eural progenitor cells into ferentiation.		
neurotoxicity, biosensor, neu	ral cell							
16. SECURITY CLASSIFICATIO	N OF:	17. LIMITATION OF	18. NUMBER	19a. NAI	ME OF RESPON	SIBLE PERSON		
a. REPORT b. ABSTRACT	c. THIS PAGE	ABSTRACT	OF	Steven	L. Stice			
	II. 1 10 1	UU	PAGES 4	19b. TEL	19b. TELEPHONE NUMBER (Include area code)			
Unclassified Unclassified	Unclassified				706-583-0071			
					Reset	Standard Form 298 (Rev. 8/98) Prescribed by ANSI Std. Z39.18		



425 River Road Athens, GA 30605

Quarterly Report Human Neural Cell-Based Biosensor

Date: December 07, 2012

Reporting Period: October 1, 2012–December 31, 2012

Prepared for: Office of Naval Research (ONR) Director, Naval Research Lab Attn: Code 5596 4555 Overlook Avenue, SW Washington, D.C. 20375-5320

Contract Number: N00014-11-C-0011, Amendment/Modification P00002

Submitted by: Dr. Steven L. Stice, Principle Investigator ArunA Biomedical, Inc. 425 River Road Athens, GA 30602 Phone: 706-583-0071 Fax: 706-262-2821 Email: <u>sstice@arunabiomedical.com</u>

Distribution Statement A: Approved for public release; distribution is unlimited.

UNCLASSIFIED

Distribution of Quarterly Report

			NUMBER OF COPIES	
ADDRESSEE	DODAAC CODE	REPORT ENCLOSED	UNCLASSIFIED/ UNLIMITED	UNCLASSIFIED/ LIMIT ED AND CLASSIFIED
Program Officer: Dr. Laura Kienker ONR Code: 342 E-Mail: laura.kienker@navy.mil	N00014	Full technical report	1	1
Administrative Contracting Officer: Office of Naval Research ONR 0254: Russelle Dunson 875 North Randolph St. Arlington, VA 22203-1995 E-mail: russelle.dunson@navy.mil	S1103A	SF 298 only	1	1
Director, Naval Research Lab Attn: Code 5596 4555 Overlook Avenue, SW Washington, D.C. 20375- 5320 E-mail: <u>reports@library.nrl.navy.mil</u>	N00173	Full technical report	1	1
Defense Technical Information Center 8725 John J. Kingman Road STE 0944 Ft. Belvoir, VA 22060-6218 E-mail: tr@dtic.mil	HJ4701	Full technical report	2	2

Summary

Our goal is to provide a more biologically relevant model of human physiology for the purpose of developing in vitro, cell based biosensors for environmental toxins. Specifically we plan to develop human neural based biosensors by using ArunA's neural cell lines derived from both human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).

This report describes the progress made in these major areas: (1) directed differentiation of hESC- and hiPSCderived neural progenitor cells into dopaminergic neurons; (2) directed differentiation of hESC- and hiPSCderived neural progenitor cells into astrocytes; (3) label-free, adhesive signature-based microfluidic cell separation; and (4) neural crest differentiation.

(1) Directed differentiation into dopaminergic neurons

We continue to make good progress on the development of a new dopaminergic progenitor cell line and dopaminergic differentiation kit for commercial release. We have narrowed down the best options for kit configurations and are continuing to optimize and edit a differentiation protocol for customer use. We are also currently in the process of repeating our dopamine release studies, as well as to further characterize our differentiated cultures for more extensive dopaminergic marker expression via immunocytochemistry and qPCR. We recently presented our results at the Annual Meeting of the Society for Neuroscience, October 13-17th, 2012, in New Orleans, LA. Preliminary work continues on translating dopaminergic neuron differentiation protocols to hiPSC-derived neural progenitor cells.

(2) Directed differentiation into astrocytes

We have made substantial progress on finishing studies delineating novel methods to differentiate hESC-derived neural progenitor cells into astrocytes significantly faster than current protocols in the literature. In fact, a manuscript on the astrocytic differentiation work has been submitted to *Stem Cell Research* for publication. Functional network based electrophysiological studies of astrocyte/neuron co-culture systems remain in progress. We are also continuing our work on translating our astrocytic differentiation protocols to hiPSC-derived neural progenitor cells.

(3) Label-free, adhesive signature-based microfluidic cell separation

Our collaboration with Georgia Tech is effectively underway toward developing a microfluidic-based approach to efficiently isolate different neural cell populations to shorten and streamline the scaled-up production of enriched populations of hiPSC-derived neural rosettes, neural progenitor cells and mature neuronal and glial cell types for direct use in cell-based assays. We are currently evaluating cell surface protein properties of our neural cell lines successfully generated under this contract in order to best optimize microfluidic cell separation methods.

(4) Neural crest differentiation

Separating and migrating from the neural tube during embryonic development and giving rise to a wide variety of cell types, neural crest cells have garnered increasing interest as new models of developmental neurotoxicity caused by environmental factors. Given the rising interest in neural crest cells as a means to create a human in vitro model to predict human health outcomes, we have begun preliminary work on differentiating our neural progenitor cells into neural crest cells following our own unique protocols.